Hologic, Inc.

NasdaqGS:HOLX Voorraadrapport

Marktkapitalisatie: US$16.9b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Hologic Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Hologic is gedaald met een gemiddeld jaarlijks percentage van -29.6%, terwijl de winst van de Medical Equipment -industrie jaarlijks groeide met 13.6%. De inkomsten zijn daalde met een gemiddeld percentage van 7.3% per jaar. Het rendement op het eigen vermogen Hologic bedraagt 10.4% en de nettomarge bedraagt 13.2%.

Belangrijke informatie

-29.63%

Groei van de winst

-26.94%

Groei van de winst per aandeel

Medical Equipment Groei van de industrie8.90%
Inkomstengroei-7.29%
Rendement op eigen vermogen10.37%
Nettomarge13.18%
Laatste winstupdate27 Dec 2025

Recente prestatie-updates uit het verleden

Recent updates

Narratiefupdate • Apr 10

HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Trading

Analysts now view Hologic’s value as effectively unchanged, with a refreshed price framework still centered around $76.67 per share as they factor in the pending $79 per share cash acquisition and recent downgrades to Hold related to the transaction’s expected early February close. Analyst Commentary Recent research focuses heavily on the pending all cash acquisition at up to $79 per share and how that affects the risk and reward for current shareholders.
Narratiefupdate • Mar 26

HOLX: Pending 79 Cash Buyout And Hold Ratings Will Shape Near-Term Outcomes

Analysts now see Hologic's fair value edging to about $76.67 per share, with only minor tweaks to growth, margin and P/E inputs. They are also reflecting increased caution around the pending up to $79 per share cash acquisition by Blackstone and TPG, which has led to a shift in ratings to Hold.
Narratiefupdate • Mar 12

HOLX: Pending 79 Cash Buyout And Hold Stance Will Guide Near-Term Outcomes

Analysts have kept their average price target for Hologic broadly unchanged at about $76.60, noting only minor tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions as they factor in the pending $79 per share acquisition by Blackstone and TPG and recent rating changes to Hold. Analyst Commentary Recent research has shifted Hologic to more of a wait and see idea, as the pending buyout at up to $79 per share becomes the main anchor for valuation and expected outcomes.
Narratiefupdate • Feb 26

HOLX: Pending 79 Cash Buyout And Hold Rating Will Define Event Path

Analysts have adjusted their price target on Hologic to $79.00 per share, reflecting updated assumptions regarding a future P/E multiple and the pending $79 per share acquisition by funds managed by Blackstone and TPG. Analyst Commentary Recent research updates have shifted toward a more neutral stance on Hologic, with the pending acquisition at $79 per share now the main reference point for valuation rather than long term growth assumptions.
Narratiefupdate • Feb 11

HOLX: Buyout Terms And Neutral Ratings Will Shape Event-Driven Returns Through 2026

Analysts have trimmed their fair value estimate for Hologic to US$76.60 from about US$76.92, citing recent downgrades to Hold and Neutral, as the pending US$79 per share buyout by Blackstone and TPG narrows the expected upside. Analyst Commentary Recent research updates around Hologic largely reflect the pending all cash acquisition at US$79 per share, with several firms moving to more neutral stances as the share price tracks closer to the agreed takeout level.
Narratiefupdate • Jan 26

HOLX: Buyout Terms And Neutral Ratings Will Frame Returns Through 2026

Narrative Update The analyst fair value estimate for Hologic has edged up by about $0.50 per share as analysts align their targets more closely with the pending private equity acquisition price of up to $79. They are also updating assumptions around the discount rate, modest revenue growth, and future P/E.
Narratiefupdate • Jan 12

HOLX: Buyout Deal Terms And Rating Downgrades Will Guide Trading Through 2026

Our updated analyst price target for Hologic edges down slightly to about $76.42 per share. This reflects that analysts now anchor their views more tightly to the proposed Blackstone and TPG takeout value of up to $79 per share and the recent wave of rating downgrades to Neutral or Hold around that deal.
Narratiefupdate • Dec 18

HOLX: Buyout Terms And Neutral Ratings Will Shape Trading Through 2026

We trim our Hologic price target slightly to approximately $76.50, as analysts coalesce around the proposed Blackstone and TPG takeout valuation of up to $79.00 per share and see limited upside beyond the agreed acquisition terms. Analyst Commentary Street research following the announced takeout has converged around the proposed valuation, with most firms adjusting ratings and targets to reflect a view that the deal price largely caps near term upside.
Narratiefupdate • Dec 04

HOLX: Buyout Deal And Neutral Ratings Will Define Shares Through 2026

The analyst price target for Hologic has inched higher by approximately $0.33 to $76.50, as analysts factor in slightly stronger long term growth and margin assumptions while anchoring valuation to the proposed Blackstone and TPG takeout price near $79 per share. Analyst Commentary Analyst reaction to the proposed Blackstone and TPG acquisition has been mixed, with most firms converging around price targets in the mid to high $70s and resetting ratings to more neutral stances as upside becomes more constrained by the agreed takeout price.
Narratiefupdate • Nov 20

HOLX: Acquisition Agreement With Blackstone and TPG Will Shape Stock Outlook Through 2026

Hologic’s analyst price target has increased modestly from $75.08 to $76.17 per share. Analysts view the proposed $79 per share acquisition by Blackstone and TPG as providing a fair valuation and setting a near-term ceiling for the stock.
Narratiefupdate • Nov 05

HOLX: Downgrades And Buyout Agreement Will Shift Near-Term Share Performance

Analysts have modestly increased their price target for Hologic from approximately $73.54 to $75.08. They cite the recently announced acquisition by Blackstone and TPG as supportive of current valuation levels, given the company's operating challenges and outlook.
Narratiefupdate • Oct 22

Analysts Raise Hologic Targets Amid Strong Results and Positive Acquisition Momentum

Hologic's analyst price target has increased by $1.11, as analysts cite improving financial performance and the impact of the recent acquisition agreement as key factors that support the higher valuation. Analyst Commentary Bullish Takeaways Bullish analysts increased their price targets, pointing to Hologic's improved financial results and raised full-year guidance amid strong recent revenue and EPS performance.
Narratiefupdate • Sep 28

Preventive Healthcare And Advanced Diagnostics Will Shape Future Markets

Despite strong quarterly outperformance, higher 2025 guidance, and increased buyout speculation, Hologic's consensus analyst price target was modestly reduced from $73.87 to $72.43 as fiscal 2025 estimates were recalibrated to reflect current demand trends and tariff expectations. Analyst Commentary Strong revenue and EPS outperformance in the recent quarter, with management raising full-year 2025 guidance.
Analyseartikel • Sep 13

Returns At Hologic (NASDAQ:HOLX) Appear To Be Weighed Down

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Narratiefupdate • Sep 05

Preventive Healthcare And Advanced Diagnostics Will Shape Future Markets

Despite strong Q3 results, raised FY25 guidance, and increased investor interest from buyout speculation, Hologic’s consensus price target remains unchanged at $73.87 as estimates are now better aligned with actual demand and tariff risks. Analyst Commentary Raised FY25 guidance and Q3 results substantially beat revenue and EPS expectations, demonstrating robust operational performance.
Analyseartikel • Aug 04

Analysts Have Made A Financial Statement On Hologic, Inc.'s (NASDAQ:HOLX) Third-Quarter Report

Investors in Hologic, Inc. ( NASDAQ:HOLX ) had a good week, as its shares rose 2.2% to close at US$67.16 following the...
Analyseartikel • Jul 19

Is Hologic, Inc. (NASDAQ:HOLX) Trading At A 38% Discount?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Hologic fair value estimate is US$103 Hologic is estimated to...
Analyseartikel • Jul 01

The Price Is Right For Hologic, Inc. (NASDAQ:HOLX)

With a price-to-earnings (or "P/E") ratio of 26.1x Hologic, Inc. ( NASDAQ:HOLX ) may be sending bearish signals at the...
Analyseartikel • Jun 13

Is Hologic (NASDAQ:HOLX) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Seeking Alpha • May 06

Hologic: Soft Performance, But Cheap Enough

Summary Hologic, Inc.'s appeal has increased due to reduced debt, serial buybacks, and modest valuations, despite recent negative organic growth and pricey acquisitions. The company has shown solid long-term growth, reducing leverage significantly and buying back shares, but recent performance has been soft with flattish sales and earnings. Despite a slight cut in earnings guidance and soft organic growth, Hologic's shares now trade at attractive multiples with very manageable leverage. While cautious due to recent underperformance and expensive acquisitions, I remain upbeat on HOLX stock and plan to add to my long position. Read the full article on Seeking Alpha
Seeking Alpha • Jan 17

Hologic: Reasonably, But Not Compellingly Valued

Summary Hologic, Inc. is down approximately 20% from recent highs despite strong quarterly results. The company continues to grow organically and via a series of 'bolt-on' acquisitions.  Management also recently added significantly to the company's stock buyback authorization. An updated analysis around Hologic, Inc. follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Oct 28

Hologic: Continued Room Amidst Bolt-On M&A Efforts

Summary Hologic, Inc.'s focus on women's health and strategic M&A, despite pandemic headwinds, positions it for continued growth with a projected $4 billion revenue in 2024. Trading at 20 times earnings, Hologic's quality and growth potential justify its valuation, with shares having risen 10% since May. The company maintains solid organic growth, reducing net debt and executing strategic acquisitions like Endomagnetics and Gynesonics, enhancing its market position. With pandemic-related diagnostics sales declining, Hologic's consistent earnings and strategic moves make it a compelling investment, despite shares not being cheap. Read the full article on Seeking Alpha
Seeking Alpha • Aug 27

Hologic Has A Lot Of Fine Qualities, But A Discount Valuation Isn't Among Them

Summary Hologic has been outperforming peers but underperforming the broader medical device sector, with shares up about 5% since my last analysis. Fiscal Q3 results showed consistent beats in Diagnostics, Breast Health, and Surgical segments, but Skeletal Health faced setbacks due to supplier issues. Management has continued to optimize the pandemic-driven surge in Panther placements, with the BV CV/TV panel growing to the second-largest panel in the company's portfolio. Hologic has been a share gainer in molecular diagnostics and is active in M&A, but long-term 5% to 7% revenue growth targets may be too challenging. Long-term revenue growth around 5%, near-term EBITDA margins in the low-30%s, and long-term FCF growth of around 6% support today's valuation and single-digit returns, but Hologic doesn't stand out as undervalued. Read the full article on Seeking Alpha

Opbrengsten en kosten

Hoe Hologic geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:HOLX Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
27 Dec 254,127544995248
27 Sep 254,101566994248
28 Jun 254,0395571,056251
29 Mar 254,0275571,045253
28 Dec 244,0397441,016266
28 Sep 244,030790995273
29 Jun 243,988702985278
30 Mar 243,961467985287
30 Dec 233,969515984286
30 Sep 234,030456988294
01 Jul 234,0384841,012297
01 Apr 234,0577531,016290
31 Dec 224,4669901,045285
24 Sep 224,8631,3021,038283
25 Jun 225,2261,5121,076284
26 Mar 225,3921,5521,092288
25 Dec 215,4941,7161,040290
25 Sep 215,6321,872994276
26 Jun 215,6632,038921257
27 Mar 215,3171,907870243
26 Dec 204,5361,384827221
26 Sep 203,7761,115840223
27 Jun 203,295497845226
28 Mar 203,325453859232
28 Dec 193,38784895240
28 Sep 193,367-204897232
29 Jun 193,315-30878225
30 Mar 193,287-11882218
29 Dec 183,258-419883217
29 Sep 183,218-111915219
30 Jun 183,207-79866227
31 Mar 183,189-132853235
30 Dec 173,1161,076838233
30 Sep 173,059756819233
01 Jul 172,983765764235
01 Apr 172,894790721231
31 Dec 162,872332686235
24 Sep 162,833331676232
25 Jun 162,809264671223
26 Mar 162,785208667221
26 Dec 152,747187647215
26 Sep 152,705132624215
27 Jun 152,641135610213

Kwaliteitswinsten: HOLX heeft een grote eenmalige verlies van $343.6M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 27th December, 2025.

Groeiende winstmarge: De huidige netto winstmarges (13.2%) HOLX } zijn lager dan vorig jaar (18.4%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van HOLX is de afgelopen 5 jaar met 29.6% per jaar gedaald.

Versnelling van de groei: De winstgroei HOLX is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.

Winst versus industrie: HOLX had het afgelopen jaar een negatieve winstgroei ( -27% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Medical Equipment ( 14.8% ).

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 10.4% ) van HOLX wordt als laag beschouwd.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/04/06 17:48
Aandelenkoers aan het einde van de dag2026/04/06 00:00
Inkomsten2025/12/27
Jaarlijkse inkomsten2025/09/27

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Hologic, Inc. wordt gevolgd door 25 analisten. 15 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
David ToungArgus Research Company
Charles ButlerBarclays
Charley JonesBarrington Research Associates, Inc.